These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21695609

  • 21. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
    Hollingworth W, Jones T, Reeves BC, Peto T.
    BMJ Open; 2017 Oct 22; 7(10):e018289. PubMed ID: 29061629
    [Abstract] [Full Text] [Related]

  • 22. [Relationship between intravitreal anti-VEGF therapy and subretinal hemorrhage in patients with exudative age-related macular degeneration].
    Kauffmann Y, Isaico R, Lefebvre A, Bron AM, Creuzot-Garcher C.
    J Fr Ophtalmol; 2014 Mar 22; 37(3):195-201. PubMed ID: 24534623
    [Abstract] [Full Text] [Related]

  • 23. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW, Bressler SB.
    Curr Opin Ophthalmol; 2013 May 22; 24(3):190-6. PubMed ID: 23492430
    [Abstract] [Full Text] [Related]

  • 24. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
    Klin Monbl Augenheilkd; 2007 Jul 22; 224(7):559-66. PubMed ID: 17657689
    [Abstract] [Full Text] [Related]

  • 25. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul 22; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 26. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
    Johnson D, Sharma S.
    Curr Opin Ophthalmol; 2013 May 22; 24(3):205-12. PubMed ID: 23518613
    [Abstract] [Full Text] [Related]

  • 27. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S.
    Health Serv J; 2012 Apr 26; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract] [Full Text] [Related]

  • 28. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
    Horsley MB, Mandava N, Maycotte MA, Kahook MY.
    Am J Ophthalmol; 2010 Oct 26; 150(4):558-561.e1. PubMed ID: 20643396
    [Abstract] [Full Text] [Related]

  • 29. [Results of an expert survey on VEGF inhibitors in ophthalmology].
    Kühn T.
    Klin Monbl Augenheilkd; 2011 Jul 26; 228(7):607-12. PubMed ID: 21472638
    [Abstract] [Full Text] [Related]

  • 30. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF.
    Acta Ophthalmol; 2015 Mar 26; 93(2):e154-9. PubMed ID: 25488124
    [Abstract] [Full Text] [Related]

  • 31. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov 26; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
    Studnička J, Rencová E, Dusová J, Marák J, Burova M, Rozsíval P, Jarkovský J, Kandrnal V.
    Cesk Slov Oftalmol; 2013 Aug 26; 69(3):96-101. PubMed ID: 24437955
    [Abstract] [Full Text] [Related]

  • 34. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
    Haddock LJ, Ramsey DJ, Young LH.
    Semin Ophthalmol; 2014 Aug 26; 29(5-6):257-62. PubMed ID: 25325851
    [Abstract] [Full Text] [Related]

  • 35. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL, Kirkpatrick L.
    BMJ; 2011 Aug 23; 343():d5058. PubMed ID: 21862536
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.
    Dedania VS, Grob S, Zhang K, Bakri SJ.
    Retina; 2015 Mar 23; 35(3):381-91. PubMed ID: 25635578
    [Abstract] [Full Text] [Related]

  • 38. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K, Pedersen TR, Sandvik L, Bragadóttir R.
    Ophthalmology; 2015 Jan 23; 122(1):146-52. PubMed ID: 25227499
    [Abstract] [Full Text] [Related]

  • 39. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep 23; 24(163):201-4. PubMed ID: 26417625
    [Abstract] [Full Text] [Related]

  • 40. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
    Yeh S, Kim SJ, Ho AC, Schoenberger SD, Bakri SJ, Ehlers JP, Thorne JE.
    Ophthalmology; 2015 Apr 23; 122(4):769-78. PubMed ID: 25576994
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.